Gossamer Bio Inc (NAS:GOSS)
$ 0.701 -0.029 (-3.97%) Market Cap: 158.58 Mil Enterprise Value: 127.31 Mil PE Ratio: 0 PB Ratio: 5.84 GF Score: 37/100

Gossamer Bio Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript

Jun 11, 2020 / 06:10PM GMT
Release Date Price: $11.53 (-6.90%)
Andrea R. Tan
Goldman Sachs Group, Inc., Research Division - Research Analyst

Good afternoon. I'm Andrea Tan from the biotechnology team at Goldman Sachs, and I'm pleased to be joined by Gossamer Bio. With us, we have Sheila Gujrathi, CEO; and Bryan Giraudo, CFO. Thanks for joining us today. Sheila, I'll turn it over to you for some opening remarks.

Sheila K. Gujrathi
Gossamer Bio, Inc. - Co-Founder, President, CEO & Director

Well, thank you so much for inviting us to the Goldman Healthcare Conference. We're really pleased to be here and looking forward to jumping into Q&A, and I have some slides here I can present along the way. But thank you, again, for including us.

Questions & Answers

Andrea R. Tan;Sheila K. Gujrathi
Goldman Sachs Group, Inc., Research Division - Research Analyst;Gossamer Bio, Inc.

Perfect. So maybe to start, can you provide a high-level overview of the company and some thoughts on how the company has advanced in the year plus since your IPO?

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot